Heart Failure
HFrEF treatment
Heart failure with reduced ejection fraction therapies
Unassessed pathwayAlso known as: HFrEF, systolic heart failure, reduced EF heart failure
100
Claims analyzed
4
Guideline recs
39
Followers
Heart Failure
Heart failure with reduced ejection fraction therapies
100 primary claims are on file, but none have been compared for agreement or contradiction yet.
ANDROMEDA, ATHENA and PALLAS
Cardiology Trials Journal Club — Tue, Aug 25, 10:00 AM EDT
Inflammatory Hypothesis of CAD
STEMI Management — Wed, Aug 12, 8:00 AM EDT — 7 attended
Tri.Fr: The Heart of the Matter
OPCI Journal Club — Fri, Aug 7, 12:00 PM EDT
Frontiers in Precision Medicine Journal Club | Opening Session
Cornell - Precision Medicine — Fri, Jul 3, 12:00 PM EDT — 1 attended
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
HFrEF treatment (also known as HFrEF, systolic heart failure, reduced EF heart failure). Heart failure with reduced ejection fraction therapies
As of 2026-10-01, the scientific consensus on HFrEF treatment is unassessed. 100 primary claims are on file, but none have been compared for agreement or contradiction yet. Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
Major professional bodies have published 4 guideline recommendations on HFrEF treatment. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hfref-treatment.
Deterministic synthesis from Synapse's enriched corpus — 216 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.
In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.
In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.
In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.
Explore every HFrEF treatment paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search HFrEF treatment papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Across this topic’s most recent indexed papers.
“Dronedarone reduces hospitalizations in symptomatic paroxysmal atrial fibrillation but increases mortality in patients with heart failure or permanent atrial fibrillation.”
“Statin therapy significantly reduces cardiovascular events in individuals with elevated hs-CRP levels.”
“Tri.Fr demonstrates durable 30-month reductions in heart failure hospitalizations for isolated tricuspid regurgitation without establishing a clear survival benefit.”